Integra Q1 Earnings Miss Estimates, Stock Down, '25 EPS Outlook Cut
IART's first-quarter 2025 earnings lag the consensus mark. Q2 revenue projections are bleak.
Compared to Estimates, Integra (IART) Q1 Earnings: A Look at Key Metrics
The headline numbers for Integra (IART) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Integra LifeSciences (IART) Q1 Earnings Miss Estimates
Integra LifeSciences (IART) came out with quarterly earnings of $0.41 per share, missing the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.55 per share a year ago.
Is This the Right Time to Hold Integra Stock in Your Portfolio?
IART stays on investors' radar courtesy of its strong prospects in the CSS segment and international growth.
Integra LifeSciences: Light At The End Of The Tunnel, Or Another Oncoming Train? (Rating Upgrade)
Integra LifeSciences had a rough 2024 as the company's quality control remediation efforts had a bigger than expected negative impact on results. Q4 '24 offered some stability with organic revenue growth and improved adjusted gross margins. 2025 guidance looks cautious, and a big cut to Q1 '25 expectations suggests that management may be pulling forward some of the lingering remediation costs.
Integra Q4 Earnings Beat Estimates, Revenues Rise Y/Y, Stock Up
IART delivers better-than-expected earnings in the fourth quarter of 2024.
Integra LifeSciences Holdings Corporation (IART) Q4 2024 Earnings Call Transcript
Integra LifeSciences Holdings Corporation (IART) Q4 2024 Earnings Call Transcript
Integra (IART) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Integra LifeSciences (IART) Surpasses Q4 Earnings Estimates
Integra LifeSciences (IART) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.89 per share a year ago.
IART vs. SONVY: Which Stock Is the Better Value Option?
Investors interested in Medical - Instruments stocks are likely familiar with Integra LifeSciences (IART) and SONOVA HOLDING (SONVY). But which of these two stocks is more attractive to value investors?
Is Integra LifeSciences (IART) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
IART or PEN: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Integra LifeSciences (IART) or Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?
